Novo Nordisk announced real-world evidence suggesting that escalating to Ozempic (semaglutide) 2 mg is associated with a 6% lower risk of major adverse cardiovascular events compared to switching to Mounjaro (tirzepatide) in type 2 diabetes patients. This finding provides a competitive advantage for Ozempic in the GLP-1 RA market, particularly for patients considering treatment intensification.
Novo Nordisk released retrospective real-world data indicating that patients with type 2 diabetes already on semaglutide 1 mg who escalated to 2 mg experienced a statistically significant 6% lower risk of major adverse cardiovascular events (MACE) compared to those who switched to tirzepatide. This is a significant competitive development as it directly compares Novo Nordisk's Ozempic (semaglutide) against Eli Lilly's Mounjaro (tirzepatide), two leading GLP-1 receptor agonists. For Novo Nordisk, this provides a strong clinical argument for continuing Ozempic treatment intensification, potentially bolstering market share and prescribing patterns. For Eli Lilly, it presents a challenge, as Mounjaro is positioned as a strong competitor, and this data could influence physician decisions regarding treatment switching. Short-term, this could lead to increased confidence in Ozempic's cardiovascular benefits, while long-term, it reinforces the importance of cardiovascular outcomes in diabetes management and intensifies the rivalry in the GLP-1 RA market.